Abstract
Despite vast improvements in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (CML) in chronic phase (CP), advanced stages of CML, accelerated phase or blast crisis, remain notoriously difficult to treat. Treatments that are highly effective against CML-CP produce disappointing results against advanced disease. Therefore, a primary goal of therapy should be to maintain patients in CP for as long as possible, by (1) striving for deep, early molecular response to treatment; (2) using tyrosine kinase inhibitors that lower risk of disease progression; and (3) more closely observing patients who demonstrate cytogenetic risk factors at diagnosis or during treatment.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1451-1462 |
| Number of pages | 12 |
| Journal | Leukemia and Lymphoma |
| Volume | 55 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2014 |
| Externally published | Yes |
Keywords
- Drug resistance
- Myeloid leukemias and dysplasias
- Tyrosine kinase inhibitor
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Fingerprint Dive into the research topics of 'Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia'. Together they form a unique fingerprint.
Cite this
Jabbour, E. J., Hughes, T. P., Cortés, J. E., Kantarjian, H. M., & Hochhaus, A. (2014). Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia and Lymphoma, 55(7), 1451-1462. https://doi.org/10.3109/10428194.2013.845883